Improving the serum stability of site-specific antibody conjugates with sulfone linkers

Bioconjugate Chemistry

Volumn 25, Issue 8, 2014, Pages 1402-1407

  Patterson, James T ^a   Asano, Shigehiro ^a   Li, Xiuling ^b   Rader, Christoph ^b   Barbas, Carlos F ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODIES; PLASMA (HUMAN); PLASMA STABILITY;

'CURRENT; ANTIBODY CONJUGATE; ANTIBODY-DRUG CONJUGATES; HUMAN PLASMAS; IN-VIVO; MALEIMIDES; SERUM PROTEINS; SERUM STABILITY; SITE-SPECIFIC; THIOETHERS;

AMINO ACIDS;

ANTIBODY CONJUGATE; CYSTEINE; MALEIMIDE; PHENYLOXADIAZOLE SULFONE; SULFONE DERIVATIVE; TRASTUZUMAB; UNCLASSIFIED DRUG; IMMUNOGLOBULIN FC FRAGMENT; MONOCLONAL ANTIBODY; OXADIAZOLE DERIVATIVE; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; SULFONE;

ANTIGEN RECOGNITION; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG CONJUGATION; HUMAN; INTERNALIZATION; MOLECULAR STABILITY; PLASMA; BINDING SITE; BLOOD; CELL LINE; CHEMICAL STRUCTURE; CHEMISTRY; ENZYME SPECIFICITY; PROTEIN CONFORMATION; PROTEIN STABILITY;

ANTIBODIES, MONOCLONAL, HUMANIZED; BINDING SITES; CELL LINE; HUMANS; IMMUNOCONJUGATES; IMMUNOGLOBULIN FC FRAGMENTS; MODELS, MOLECULAR; OXADIAZOLES; PROTEIN CONFORMATION; PROTEIN STABILITY; SINGLE-CHAIN ANTIBODIES; SUBSTRATE SPECIFICITY; SULFONES; TRASTUZUMAB;

EID: 84906345897     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/bc500276m     Document Type: Article

References (37)

1. Chari, R. V., Miller, M. L., and Widdison, W. C. (2014) Antibody-drug conjugates: an emerging concept in cancer therapy Angew. Chem., Int. Ed. 53, 3796-827
2. Carter, P. J. and Senter, P. D. (2008) Antibody-drug conjugates for cancer therapy Cancer J. 14, 154-69
3. Sievers, E. L. and Senter, P. D. (2013) Antibody-drug conjugates in cancer therapy Annu. Rev. Med. 64, 15-29
4. Lambert, J. M. (2013) Drug-conjugated antibodies for the treatment of cancer Br. J. Clin. Pharmacol. 76, 248-62
5. Strop, P., Liu, S. H., Dorywalska, M., Delaria, K., Dushin, R. G., Tran, T. T., Ho, W. H., Farias, S., Casas, M. G., Abdiche, Y., Zhou, D., Chandrasekaran, R., Samain, C., Loo, C., Rossi, A., Rickert, M., Krimm, S., Wong, T., Chin, S. M., Yu, J., Dilley, J., Chaparro-Riggers, J., Filzen, G. F., O'Donnell, C. J., Wang, F., Myers, J. S., Pons, J., Shelton, D. L., and Rajpal, A. (2013) Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates Chem. Biol. 20, 161-7
6. Alley, S. C., Benjamin, D. R., Jeffrey, S. C., Okeley, N. M., Meyer, D. L., Sanderson, R. J., and Senter, P. D. (2008) Contribution of linker stability to the activities of anticancer immunoconjugates Bioconjugate Chem. 19, 759-65
7. Doronina, S. O., Toki, B. E., Torgov, M. Y., Mendelsohn, B. A., Cerveny, C. G., Chace, D. F., DeBlanc, R. L., Gearing, R. P., Bovee, T. D., Siegall, C. B., Francisco, J. A., Wahl, A. F., Meyer, D. L., and Senter, P. D. (2003) Development of potent monoclonal antibody auristatin conjugates for cancer therapy Nat. Biotechnol. 21, 778-84
8. Lewis Phillips, G. D., Li, G., Dugger, D. L., Crocker, L. M., Parsons, K. L., Mai, E., Blattler, W. A., Lambert, J. M., Chari, R. V., Lutz, R. J., Wong, W. L., Jacobson, F. S., Koeppen, H., Schwall, R. H., Kenkare-Mitra, S. R., Spencer, S. D., and Sliwkowski, M. X. (2008) Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate Cancer Res. 68, 9280-90
9. Polson, A. G., Calemine-Fenaux, J., Chan, P., Chang, W., Christensen, E., Clark, S., de Sauvage, F. J., Eaton, D., Elkins, K., Elliott, J. M., Frantz, G., Fuji, R. N., Gray, A., Harden, K., Ingle, G. S., Kljavin, N. M., Koeppen, H., Nelson, C., Prabhu, S., Raab, H., Ross, S., Slaga, D. S., Stephan, J. P., Scales, S. J., Spencer, S. D., Vandlen, R., Wranik, B., Yu, S. F., Zheng, B., and Ebens, A. (2009) Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection Cancer Res. 69, 2358-64
10. Hamblett, K. J., Senter, P. D., Chace, D. F., Sun, M. M., Lenox, J., Cerveny, C. G., Kissler, K. M., Bernhardt, S. X., Kopcha, A. K., Zabinski, R. F., Meyer, D. L., and Francisco, J. A. (2004) Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate Clin. Cancer Res. 10, 7063-70
11. Wang, L., Amphlett, G., Blattler, W. A., Lambert, J. M., and Zhang, W. (2005) Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry Protein Sci. 14, 2436-46
12. Boswell, C. A., Mundo, E. E., Zhang, C., Bumbaca, D., Valle, N. R., Kozak, K. R., Fourie, A., Chuh, J., Koppada, N., Saad, O., Gill, H., Shen, B. Q., Rubinfeld, B., Tibbitts, J., Kaur, S., Theil, F. P., Fielder, P. J., Khawli, L. A., and Lin, K. (2011) Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody-drug conjugates in rats Bioconjugate Chem. 22, 1994-2004
13. Jeffrey, S. C., Burke, P. J., Lyon, R. P., Meyer, D. W., Sussman, D., Anderson, M., Hunter, J. H., Leiske, C. I., Miyamoto, J. B., Nicholas, N. D., Okeley, N. M., Sanderson, R. J., Stone, I. J., Zeng, W., Gregson, S. J., Masterson, L., Tiberghien, A. C., Howard, P. W., Thurston, D. E., Law, C. L., and Senter, P. D. (2013) A potent anti-CD70 antibody-drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation technology Bioconjugate Chem. 24, 1256-63
14. Panowksi, S., Bhakta, S., Raab, H., Polakis, P., and Junutula, J. R. (2014) Site-specific antibody drug conjugates for cancer therapy mAbs 6, 1-12
15. Junutula, J. R., Raab, H., Clark, S., Bhakta, S., Leipold, D. D., Weir, S., Chen, Y., Simpson, M., Tsai, S. P., Dennis, M. S., Lu, Y., Meng, Y. G., Ng, C., Yang, J., Lee, C. C., Duenas, E., Gorrell, J., Katta, V., Kim, A., McDorman, K., Flagella, K., Venook, R., Ross, S., Spencer, S. D., Lee Wong, W., Lowman, H. B., Vandlen, R., Sliwkowski, M. X., Scheller, R. H., Polakis, P., and Mallet, W. (2008) Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index Nat. Biotechnol. 26, 925-32
16. Shen, B. Q., Xu, K., Liu, L., Raab, H., Bhakta, S., Kenrick, M., Parsons-Reponte, K. L., Tien, J., Yu, S. F., Mai, E., Li, D., Tibbitts, J., Baudys, J., Saad, O. M., Scales, S. J., McDonald, P. J., Hass, P. E., Eigenbrot, C., Nguyen, T., Solis, W. A., Fuji, R. N., Flagella, K. M., Patel, D., Spencer, S. D., Khawli, L. A., Ebens, A., Wong, W. L., Vandlen, R., Kaur, S., Sliwkowski, M. X., Scheller, R. H., Polakis, P., and Junutula, J. R. (2012) Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates Nat. Biotechnol. 30, 184-9
17. Junutula, J. R., Flagella, K. M., Graham, R. A., Parsons, K. L., Ha, E., Raab, H., Bhakta, S., Nguyen, T., Dugger, D. L., Li, G., Mai, E., Lewis Phillips, G. D., Hiraragi, H., Fuji, R. N., Tibbitts, J., Vandlen, R., Spencer, S. D., Scheller, R. H., Polakis, P., and Sliwkowski, M. X. (2010) Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer Clin. Cancer Res. 16, 4769-78
18. Dornan, D., Bennett, F., Chen, Y., Dennis, M., Eaton, D., Elkins, K., French, D., Go, M. A., Jack, A., Junutula, J. R., Koeppen, H., Lau, J., McBride, J., Rawstron, A., Shi, X., Yu, N., Yu, S. F., Yue, P., Zheng, B., Ebens, A., and Polson, A. G. (2009) Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma Blood 114, 2721-9
19. Junutula, J. R., Bhakta, S., Raab, H., Ervin, K. E., Eigenbrot, C., Vandlen, R., Scheller, R. H., and Lowman, H. B. (2008) Rapid identification of reactive cysteine residues for site-specific labeling of antibody-Fabs J. Immunol. Methods 332, 41-52
20. Lin, D., Saleh, S., and Liebler, D. C. (2008) Reversibility of covalent electrophile-protein adducts and chemical toxicity Chem. Res. Toxicol. 21, 2361-9
21. Toda, N., Asano, S., and Barbas, C. F., 3rd. (2013) Rapid, stable, chemoselective labeling of thiols with Julia-Kocienski-like reagents: a serum-stable alternative to maleimide-based protein conjugation Angew. Chem., Int. Ed. 52, 12592-6
22. Lewis, M. R. and Shively, J. E. (1998) Maleimidocysteineamido-DOTA derivatives: new reagents for radiometal chelate conjugation to antibody sulfhydryl groups undergo pH-dependent cleavage reactions Bioconjugate Chem. 9, 72-86
23. Jackson, D., Atkinson, J., Guevara, C. I., Zhang, C., Kery, V., Moon, S. J., Virata, C., Yang, P., Lowe, C., Pinkstaff, J., Cho, H., Knudsen, N., Manibusan, A., Tian, F., Sun, Y., Lu, Y., Sellers, A., Jia, X. C., Joseph, I., Anand, B., Morrison, K., Pereira, D. S., and Stover, D. (2014) In vitro and in vivo evaluation of cysteine and site specific conjugated herceptin antibody-drug conjugates PLoS One 9, e83865
24. Morales-Sanfrutos, J., Lopez-Jaramillo, J., Ortega-Munoz, M., Megia-Fernandez, A., Perez-Balderas, F., Hernandez-Mateo, F., and Santoyo-Gonzalez, F. (2010) Vinyl sulfone: a versatile function for simple bioconjugation and immobilization Org. Biomol. Chem. 8, 667-75
25. Hofer, T., Thomas, J. D., Burke, T. R., Jr., and Rader, C. (2008) An engineered selenocysteine defines a unique class of antibody derivatives Proc. Natl. Acad. Sci. U. S. A. 105, 12451-6
26. Hofer, T., Skeffington, L. R., Chapman, C. M., and Rader, C. (2009) Molecularly defined antibody conjugation through a selenocysteine interface Biochemistry 48, 12047-57
27. Li, X., Yang, J., and Rader, C. (2014) Antibody conjugation via one and two C-terminal selenocysteines Methods 65, 133-8
28. Kim, C. H., Axup, J. Y., Lawson, B. R., Yun, H., Tardif, V., Choi, S. H., Zhou, Q., Dubrovska, A., Biroc, S. L., Marsden, R., Pinstaff, J., Smider, V. V., and Schultz, P. G. (2013) Bispecific small molecule-antibody conjugate targeting prostate cancer Proc. Natl. Acad. Sci. U. S. A. 110, 17796-801
29. Hutchins, B. M., Kazane, S. A., Staflin, K., Forsyth, J. S., Felding-Habermann, B., Smider, V. V., and Schultz, P. G. (2011) Selective formation of covalent protein heterodimers with an unnatural amino acid Chem. Biol. 18, 299-303
30. Kim, C. H., Axup, J. Y., Dubrovska, A., Kazane, S. A., Hutchins, B. A., Wold, E. D., Smider, V. V., and Schultz, P. G. (2012) Synthesis of bispecific antibodies using genetically encoded unnatural amino acids J. Am. Chem. Soc. 134, 9918-21
31. Rader, C. (2014) Chemically programmed antibodies Trends Biotechnol. 32, 186-97
32. Cui, H., Thomas, J. D., Burke, T. R., Jr., and Rader, C. (2012) Chemically programmed bispecific antibodies that recruit and activate T cells J. Biol. Chem. 287, 28206-14
33. Gavrilyuk, J. I., Wuellner, U., Salahuddin, S., Goswami, R. K., Sinha, S. C., and Barbas, C. F., III (2009) An efficient chemical approach to bispecific antibodies and antibodies of high valency Bioorg. Med. Chem. Lett. 19, 3716-20
34. Gavrilyuk, J., Ban, H., Nagano, M., Hakamata, W., and Barbas, C. F., III (2012) Formylbenzene diazonium hexafluorophosphate reagent for tyrosine-selective modification of proteins and the introduction of a bioorthogonal aldehyde Bioconjugate Chem. 23, 2321-8
35. Ban, H., Nagano, M., Gavrilyuk, J., Hakamata, W., Inokuma, T., and Barbas, C. F., III (2013) Facile and stabile linkages through tyrosine: bioconjugation strategies with the tyrosine-click reaction Bioconjugate Chem. 24, 520-32
36. Guo, J., Kumar, S., Prashad, A., Starkey, J., and Singh, S. K. (2014) Assessment of physical stability of an antibody drug conjugate by higher order structure analysis: impact of thiol- maleimide chemistry Pharm. Res. 31, 1710-23
37. Beckley, N. S., Lazzareschi, K. P., Chih, H. W., Sharma, V. K., and Flores, H. L. (2013) Investigation into temperature-induced aggregation of an antibody drug conjugate Bioconjugate Chem. 24, 1674-83